TUKYSA Drug Patent Profile

When do Tukysa patents expire, and when can generic versions of Tukysa launch?

Tukysa is a drug marketed by Seagen and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and eighty-seven patent family members in forty-four countries.

The generic ingredient in TUKYSA is tucatinib. One supplier is listed for this compound. Additional details are available on the tucatinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Tukysa

Tukysa was eligible for patent challenges on April 17, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 12, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TUKYSA

International Patents:	187
US Patents:	7
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TUKYSA

TUKYSA is protected by seven US patents and three FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-002	Apr 17, 2020		RX	Yes	Yes
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No			Y	Y
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No			Y
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-002	Apr 17, 2020		RX	Yes	Yes
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-002	Apr 17, 2020		RX	Yes	Yes

International Patents for TUKYSA

When does loss-of-exclusivity occur for TUKYSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

New Zealand

Norway

Philippines

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TUKYSA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	5134548
Turkey	201808450
Canada	2867723
Singapore	152230
Serbia	56608	ČVRSTA DISPERZIJA (SOLID DISPERSION)
South Korea	20140075798

Supplementary Protection Certificates for TUKYSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1971601	C202130042	Spain		PRODUCT NAME: TUCATINIB, OPCIONALMENTE EN FORMA DE UNA SAL O SOLVATO ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/20/1526; DATE OF AUTHORISATION: 20210211; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1526; DATE OF FIRST AUTHORISATION IN EEA: 20210211
1971601	770	Finland
1971601	C 2021 022	Romania		PRODUCT NAME: TUCATINIB OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC SAU SOLVAT; NATIONAL AUTHORISATION NUMBER: EU/1/20/1526; DATE OF NATIONAL AUTHORISATION: 20210211; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1526; DATE OF FIRST AUTHORISATION IN EEA: 20210211
1971601	PA2021516,C1971601	Lithuania		PRODUCT NAME: TUKATINIBAS, PASIRINKTINAI FARMACISKAI PRIIMTINOS DRUSKOS ARBA SOLVATO PAVIDALU; REGISTRATION NO/DATE: EU/1/20/1526 20210211
1971601	2021C/531	Belgium		PRODUCT NAME: TUCATINIB, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; AUTHORISATION NUMBER AND DATE: EU/1/20/1526 20210212
1971601	27/2021	Austria		PRODUCT NAME: TUCATINIB; REGISTRATION NO/DATE: EU/1/20/1526 (MITTEILUNG) 20210212

Investment Scenario, Market Dynamics, and Financial Trajectory for TUKYSA

Last updated: February 3, 2026

Summary

TUKYSA (tucatinib), a selective HER2-directed tyrosine kinase inhibitor developed by Seagen (formerly Seattle Genetics), entered the oncology market positioning itself as a targeted therapy for HER2-positive breast cancer. Its market debut was supported by clinical efficacy data, regulatory approvals, and strategic partnerships aimed at establishing its footprint in breast cancer treatment. This analysis explores TUKYSA’s current market landscape, projected growth, competitive positioning, and financial outlook, emphasizing its potential as an investment opportunity within the oncology pharmaceutical sector.

---

What Is TUKYSA and Its Clinical Context?

TUKYSA (tucatinib) is approved for:

• Advanced unresectable or metastatic HER2-positive breast cancer, specifically after trastuzumab-based therapy.
• As part of combination regimens with trastuzumab and capecitabine.

Key features:

Attribute	Specification
Molecular Class	Selective HER2 tyrosine kinase inhibitor
Indications	HER2-positive breast cancer (metastatic and locally advanced)
Approval Date	April 2020 (FDA), August 2021 (EMA)
Regulatory Agencies	FDA, EMA, Health Canada, others
Patent Expiry	Approx. 2037 (pending patent life and exclusivity extensions)

---

Market Dynamics

1. Industry Landscape and Competitive Positioning

TUKYSA operates within a highly competitive oncology pharmacotherapy space, with key rivals including:

Competitor	Mechanism	Indications	Market Share (2022)	Price Range (per treatment cycle)
Kadcyla (ado-trastuzumab emtansine)	Antibody-drug conjugate	HER2-positive breast cancer	~25%	$10,000 - $12,000
Perjeta (pertuzumab)	Monoclonal antibody	HER2-positive breast cancer	~20%	$6,000 - $8,000
Nerlynx (neratinib)	Tyrosine kinase inhibitor	Extended adjuvant therapy	-	$7,000 - $9,000
tucatinib	Tyrosine kinase targeting HER2	Targeted therapy	Growing	$8,000 - $10,000

Market share estimations indicate rapid adoption driven by TUKYSA's favorable safety profile and efficacy data, especially in patients with brain metastases, uncommon in other HER2-targeted agents.

2. Market Size and Segmentation

Global HER2-positive breast cancer market (2022 estimate):

Segment	Valuation (USD Billion)	CAGR (2022–2028)	Notes
Total	$8.4B	12.5%	Driven by increased screening and targeted therapies
First-line treatments	$4.0B	10%	Dominated by trastuzumab + pertuzumab
Second-line & beyond	$4.4B	15%	Growing interest in Tucatinib, Neratinib, T-DM1

TUKYSA’s addressable patient population:

• U.S. (approx. 30,000 new cases annually)
• Europe (approx. 20,000)
• Asia-Pacific (expanding, with large emerging markets)

3. Adoption Drivers and Barriers

Drivers:

• Proven superior CNS efficacy in HER2-positive brain metastases
• Favorable side effect profile compared to chemotherapies
• Strategic partnerships (e.g., with Roche/Genentech for global sales rights)

Barriers:

• High treatment costs (~$8,000–$10,000 per cycle)
• Competition from established therapies
• Physician familiarity and formulary inclusion delays

---

Financial Trajectory and Investment Outlook

1. Revenue Projections

2023–2028 revenue forecast (USD Millions):

Year	Estimated Revenue	Growth Rate	Assumptions
2023	$400M	50%	Early adoption, expanding indications
2024	$600M	50%	Broader regional launches, clinical trial data support
2025	$900M	50%	Adoption in third-line therapy, CNS efficacy influencing prescribing
2026	$1.2B	33%	Market penetration in Asia-Pacific, additional label expansions
2027	$1.5B	25%	Increased combination therapy use
2028	$1.8B	20%	Market saturation, stable therapeutic placement

2. Cost Structure and Margins

Aspect	Details
R&D expenditure	Approx. $200M annually (2023–2025)
Manufacturing costs	20–30% of revenue
Gross margin	Estimated at 70–75% post-expense
Operating costs	Includes marketing, distribution, admin (~30% of revenue)

3. Profitability Potential

• Break-even expected by 2024–2025 based on revenue growth
• Margin expansion linked to volume sales, efficiency improvements
• Investment in global markets and expanding indications bolsters long-term revenue

---

Comparison With Competitors: Market Positioning & Financial Trajectory

Parameter	TUKYSA	Kadcyla	Perjeta	Nerlynx
Mechanism	HER2 TKI	Antibody-Drug Conjugate	Monoclonal Ab	TKI
FDA Approval Year	2020	2013	2012	2018
Patient Population	Metastatic HER2+	HER2+	HER2+	Extended adjuvant
Peak Sales (Est.)	$2B	$3B	$2.5B	$1.2B
Key Differentiator	CNS efficacy	Proven efficacy	In combo therapy	Extended treatment

---

Regulatory and Policy Considerations

• Continued approval extensions for TUKYSA should hinge on ongoing phase III trials (HER2CLIMB and expansions)
• Path to label expansions includes earlier-line indications and adjuvant settings
• Reimbursement policies will significantly influence uptake; payers favor targeted, well-tolerated therapies

---

Deep-Dive: Key Market Trends and Strategic Factors

1. Expansion into CNS Indications

TUKYSA uniquely demonstrates activity in brain metastases, positioning it advantageously in a subset with limited options.

2. Combination Therapy Strategies

Future growth depends on:

• Efficacy in combination regimens
• Clinical trials validating new lines of use
• Regulatory approvals for expanded indications

3. Geographic Expansion

• Focus on Asia-Pacific and emerging markets
• Local manufacturing and pricing strategies critical

4. Pricing and Reimbursement Dynamics

• Payers are increasingly scrutinizing cost-effectiveness
• Outcomes-based reimbursement models likely

---

Summary of Investment Insights

Aspect	Key Point
Growth drivers	CNS efficacy, combination strategies, rapid adoption
Challenges	Cost, competition, regulatory delays
Revenue potential	Multi-billion dollar peak sales achievable within 5 years
Strategic opportunities	Expanded indications, geographic reach, partner collaborations

---

Key Takeaways

• Market Position: TUKYSA occupies a niche in HER2-positive breast cancer with a proven benefit in CNS metastases, differentiating it within the crowded targeted therapy landscape.
• Growth Outlook: Aggressive expansion through clinical trials and geographic markets could propel revenue towards $1.8–2 billion by 2028.
• Competitive Landscape: Its differentiation in CNS activity provides a strategic edge over competitors like Kadcyla and Perjeta.
• Investment Risks: Price pressures, regulatory hurdles, and rapid development of new agents pose potential headwinds.
• Long-term Value: With patent protection until approximately 2037 and expanding indications, TUKYSA offers a compelling long-term investment profile.

---

FAQs

Q1: What are the main advantages of TUKYSA over other HER2-targeted therapies?
A1: Its high selectivity for HER2 and demonstrated efficacy in treating brain metastases provide a significant advantage, especially for patients with CNS involvement—a previously limited treatment domain.

Q2: How does TUKYSA’s pricing compare to other targeted therapies?
A2: The treatment cycle costs hover around $8,000 to $10,000, comparable or slightly higher than similar targeted agents, justified by its clinical benefits and CNS activity.

Q3: What is the outlook on TUKYSA’s approved indications?
A3: Currently approved for metastatic HER2-positive breast cancer post-trastuzumab therapy; ongoing trials aim to expand to first-line and adjuvant settings, increasing market potential.

Q4: Which regions are targeted for global expansion?
A4: The focus includes Europe, Japan, and Asia-Pacific markets, where HER2-positive breast cancer is prevalent and unmet medical needs persist.

Q5: What are the main risks affecting TUKYSA’s market adoption?
A5: Market penetration could be hindered by high costs, competition from established therapies, and possible delays in regulatory approvals for expanded indications.

---

Sources

1. U.S. Food and Drug Administration. (2020). FDA approves tucatinib for breast cancer.
2. European Medicines Agency. (2021). TUKYSA approval overview.
3. Seagen Inc. Annual Reports (2022–2023).
4. Market Research Future. (2022). HER2-positive breast cancer therapeutics market report.
5. ClinicalTrials.gov. (2023). Tucatinib ongoing clinical trials.

Note: This article synthesizes current market data and projections as of early 2023; future developments may alter the landscape.